生命科学资讯

Introducing Endpoints Signal — intelligence for fresh biopharma insights

Gene writing startup Tessera strikes $150M partnership with Regeneron

Protego gets $130M for AL amyloidosis drug from leaders behind Vyndaqel

Generate:Biomedicines to start Phase 3 studies for TSLP antibody

Novo’s MFN prices to supersede IRA prices for Ozempic, Wegovy, CMS says

Lundbeck backs out of bidding war for sleep disorder biotech Avadel

Novo submits high-dose Wegovy for FDA approval using voucher

Delayed panel on vaccine injury payments to meet next month

Imfinzi's latest label expansion; FDA seeks more information on BiomX's nebulizer

FDA pushes back Ascendis' dwarfism drug decision date by three months

China's Zhongmou seeks to create a ‘one-size-fits-all’ rival to Luxturna

Cormorant eyes another $400M healthcare fund

Sanofi headquarters raided in broader French tax fraud investigation

Kallyope scraps one of two mid-stage migraine drugs

Otsuka’s anti-APRIL antibody gets FDA approval for kidney disease IgAN

CMS unveils IRA prices for Ozempic, Wegovy and other drugs from second round

What a team of ex-Amazon employees are building next in healthcare

Pharma faces deadline to bring IRA fight to Supreme Court as first set of negotiated prices looms

FDA OKs Sarepta study of new immune suppression approach with Elevidys; Gilead buys preclinical TREX1 program

Novo Nordisk’s amycretin cuts body weight, blood sugar in Phase 2 diabetes trial